Australia markets closed

Navidea Biopharmaceuticals, Inc. (NAVB)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0381+0.0005 (+1.33%)
At close: 01:08PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.81M
Enterprise value 1.21M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.33k
Price/book (mrq)N/A
Enterprise value/revenue 1.98k
Enterprise value/EBITDA -0.12

Trading information

Stock price history

Beta (5Y monthly) 1.15
52-week change 3-83.43%
S&P500 52-week change 322.36%
52-week high 30.2720
52-week low 30.0210
50-day moving average 30.0398
200-day moving average 30.0588

Share statistics

Avg vol (3-month) 3107.31k
Avg vol (10-day) 348.83k
Shares outstanding 5100.08M
Implied shares outstanding 6100.08M
Float 864.07M
% held by insiders 135.89%
% held by institutions 10.01%
Shares short (15 Sept 2023) 42.69M
Short ratio (15 Sept 2023) 40.52
Short % of float (15 Sept 2023) 43.96%
Short % of shares outstanding (15 Sept 2023) 42.68%
Shares short (prior month 15 Aug 2023) 4534.87k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 326 Apr 2019
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 326 Apr 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,678,791.02%

Management effectiveness

Return on assets (ttm)-107.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)610
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -10.13M
Net income avi to common (ttm)-8.81M
Diluted EPS (ttm)-0.2000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.86M
Total cash per share (mrq)0.04
Total debt (mrq)1.26M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.56
Book value per share (mrq)-0.03

Cash flow statement

Operating cash flow (ttm)-9.71M
Levered free cash flow (ttm)-7.77M